Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
Cav 2.2
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "Cav 2.2" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
Cav 2.2 blocker 1 is an orally active N-type calcium channel (Cav 2.2) blocker. Cav 2.2 blocker 1 can be used for research on neuropathic pain .
Cat. No.: HY-120751
CAS No.: 1309601-26-0
Target:
Research Areas:
TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC50 value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .
Synonyms: 5,6-EET; (±)5,6-EpETrE
Target:
Research Areas:
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
Cat. No.: HY-164803
CAS No.: 1281060-70-5
Target:
Research Areas:
CBD3063 is a selective modulator of collapsin response mediator protein 2 (CRMP2). CBD3063 uncouples Cav2.2 from CRMP2. CBD3063 reverses neuropathic and inflammatory pain by reducing membrane expression of CaV2.2 .
Target:
Research Areas:
Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid .
Cat. No.: HY-P3269
CAS No.: 178805-91-9
Target:
Research Areas:
Target:
Research Areas:
BTT-266 is an antagonist forcalcium channel, through suppression of the CaVα1-AID-CaVβ3 interaction, with a Ki of 1.4 μM. BTT-266 modulates the activation of voltage-dependent CaV2.2. BTT-266 exhibits analgesic efficacy against neuropathic pain in rats model .
Cat. No.: HY-148866
CAS No.: 2143584-82-9
Target:
Research Areas:
Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively .
Cat. No.: HY-44153
CAS No.: 689297-68-5
Target:
Research Areas:
KV2 channel inhibitor-1 is a selective KV2 channel inhibitor with IC50s of 0.2 μM and 0.41 μM for KV2.1 and KV2.2, respectively. KV2 channel inhibitor-1 possesses good selectivity over KV1.2 (IC50>10 μM). KV2 channel inhibitor-1 is >10-fold selective over NaV channels and other KV channels and displays weak activity on CaV channels .
Cat. No.: HY-P10898
CAS No.: 2900996-95-2
Target:
Research Areas:
Cat. No.: HY-147639
CAS No.: 2987640-67-3
Target:
Research Areas:
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .
Cat. No.: HY-175226
CAS No.: 3109603-86-0
Research Areas:
DPP8/9-IN-2 (Compound 21) is a DPP8/9 inhibitor with IC50 values of 0.22 nM and 3 nM, respectively, and Ki values of 2.9 nM and 6 nM, respectively . DPP8/9-IN-2 has certain cardiotoxicity, with IC50 values of 0.7 μM, 29.0 μM and 27.7 μM for hERG potassium channel, Nav1.5 sodium channel and Cav1.2 calcium channel, respectively. DPP8/9-IN-2 can be used in the research of diseases such as tumors .
Cat. No.: HY-116307
CAS No.: 35763-29-2
Target:
Research Areas:
2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
Cat. No.: HY-181612
Research Areas:
COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC50 of 0.26 μM and a CaV2.2 IC50 of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain .
Cat. No.: HY-169845
CAS No.: 687568-35-0
Target:
Research Areas:
Calcium Channel antagonist 6 (Compound 328) is a highly selective antagonist of voltage-gated calcium channel CaV2.2 with an IC50 value of 0.37 μM. Calcium Channel antagonist 6 inhibits of neuron depolarization-induced Ca 2+ influx. Calcium Channel antagonist 6 is promising for research of neuropathic pain .
Cat. No.: HY-P5874
Target:
Research Areas:
Cat. No.: HY-P5813
Synonyms: β-TRTX-cd1a; β-Theraphotoxin-cd1a
Target:
Research Areas:
Cat. No.: HY-RS01792
Target:
Research Areas:
CACNA1B Human Pre-designed siRNA Set A contains three designed siRNAs for CACNA1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P5796
Target:
Research Areas:
Cat. No.: HY-115596
CAS No.: 2413939-96-3
Target:
Research Areas:
BTT-369 is a CaVα1·CaVβ3 protein-protein complex antagonist with a Ki of 2.0 μM. BTT-369 inhibits CaV2.2 currents, with an apparent IC50 value of 31 μM. BTT-369 disrupts the interaction between CaVα1 and CaVβ3 subunits. BTT-369 reduces the current density of CaV2.2, and shifts the voltage dependence of steady-state inactivation and activation of CaV2.2 to more positive potentials. BTT-369 alleviates mechanical hyperalgesia in a rat model of tibial nerve injury. BTT-369 can be used for the study of neuropathic pain .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
